New China FDA Rules Allow Resumption Of Clinical Genome Sequencing
This article was originally published in PharmAsia News
China's State FDA said it now has new rules in place covering the tools of the practice, allowing genome sequencing to resume in the country after a nearly five-month hiatus.
You may also be interested in...
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.